Microbiota from patients with ulcerative colitis promote colorectal carcinogenesis in mice

Tian, Yun; Zuo, Lugen; Guo, Bing; Wu, Huayue; He, Yifan; Xu, Zhenzhen; Shen, Mengdi; Hu, Jian-Guo; Qian, Jun

doi:10.1016/j.nut.2022.111712

Cited by 6 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the genus level, treatment with YS108R EPS exhibited dramatically higher levels of Coriobacteriaceae UCG-002 , Butyricimonas , Parabacteroides , Ruminococcaceae UCG-010 , Ruminococcaceae UCG-014 , and Candidatus Saccharimonas . Coriobacteriaceae UCG-002 is a saccharolytic bacterial species that can metabolize a variety of carbohydrates and possesses anti-inflammatory properties. − Butyricimonas promotes colonocyte function recovery and Treg cell development, is negatively correlated with pro-inflammatory gene expression, and has been confirmed to alleviate inflammation-related diseases and members of Parabacteroides showed anticolitis, anticolorectal cancer (CRC), and antiobesity capacity …”

Section: Discussionmentioning

confidence: 99%

Exopolysaccharides Produced by Bifidobacterium longum subsp. longum YS108R Ameliorates DSS-Induced Ulcerative Colitis in Mice by Improving the Gut Barrier and Regulating the Gut Microbiota

Li,

Stanton

et al. 2024

J. Agric. Food Chem.

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a major disease that has endangered human health. Our previous study demonstrated that Bifidobacterium longum subsp. longum YS108R, a ropy exopolysaccharide (EPS)-producing bacterium, could alleviate UC in mice, but it is unclear whether EPS is the key substance responsible for its action. In this study, we proposed to investigate the remitting effect of EPS from B. longum subsp. longum YS108R on UC in a DSS-induced UC mouse model. Water extraction and alcohol precipitation were applied to extract EPS from the supernatant of B. longum subsp. longum YS108R culture. Then the animal trial was performed, and the results indicated that YS108R EPS ameliorated colonic pathological damage and the intestinal barrier. YS108R EPS suppressed inflammation via NF-κB signaling pathway inhibition and attenuated oxidative stress via the Nrf2 signaling pathway activation. Remarkably, YS108R EPS regulated gut microbiota, as evidenced by an increase in short-chain fatty acid (SCFA)-producing bacteria and a decline in Gram-negative bacteria, resulting in an increase of propionate and butyrate and a reduction of lipopolysaccharide (LPS). Collectively, YS108R EPS manipulated the intestinal microbiota and its metabolites, which further improved the intestinal barrier and inhibited inflammation and oxidative stress, thereby alleviating UC.

show abstract

Section: Discussionmentioning

confidence: 99%

Exopolysaccharides Produced by Bifidobacterium longum subsp. longum YS108R Ameliorates DSS-Induced Ulcerative Colitis in Mice by Improving the Gut Barrier and Regulating the Gut Microbiota

Li,

Stanton

et al. 2024

J. Agric. Food Chem.

View full text Add to dashboard Cite

show abstract

“…Therapeutic methods of gut microbiota modification, including FMT and symbiotics, are in the early stages of investigation. Recent research on mouse models has demonstrated a reversal in the microbiome associated with colonic dysplasia post-FMT, with several studies showing near reversal of colonic dysplasia and a significant reduction in pro-oncogenic inflammatory cytokines [ 114 , 115 , 116 , 117 ]. These models also show the modulation of immunotherapy efficacy post-FMT.…”

Section: Fecal Microbiota Transplantation In Colorectal Cancermentioning

confidence: 99%

“…These findings include the following: (1) A healthier microbiome is associated with a higher percentage of Firmicutes than Bacteroides [ 117 ]. (2) Higher alpha diversity is associated with FMT from control groups without CRC [ 115 , 117 ]. (3) Lesser dysplasia, tumor counts, improved mice weight, and longer intestinal lengths are observed in mice receiving FMT from healthy controls [ 114 , 115 , 117 ].…”

Section: Fecal Microbiota Transplantation In Colorectal Cancermentioning

confidence: 99%

Gut Microbiome–Colorectal Cancer Relationship

Yadav,

Sainatham,

Filippov

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Traditionally, the role of gut dysbiosis was thought to be limited to pathologies like Clostridioides difficile infection, but studies have shown its role in other intestinal and extraintestinal pathologies. Similarly, recent studies have surfaced showing the strong potential role of the gut microbiome in colorectal cancer, which was traditionally attributed mainly to sporadic or germline mutations. Given that it is the third most common cancer and the second most common cause of cancer-related mortality, 78 grants totaling more than USD 28 million have been granted to improve colon cancer management since 2019. Concerted efforts by several of these studies have identified specific bacterial consortia inducing a proinflammatory environment and promoting genotoxin production, causing the induction or progression of colorectal cancer. In addition, changes in the gut microbiome have also been shown to alter the response to cancer chemotherapy and immunotherapy, thus changing cancer prognosis. Certain bacteria have been identified as biomarkers to predict the efficacy of antineoplastic medications. Given these discoveries, efforts have been made to alter the gut microbiome to promote a favorable diversity to improve cancer progression and the response to therapy. In this review, we expand on the gut microbiome, its association with colorectal cancer, and antineoplastic medications. We also discuss the evolving paradigm of fecal microbiota transplantation in the context of colorectal cancer management.

show abstract

“…All mice underwent weekly general assessments, including body weight measurements and food and water intake measurements. Additionally, the disease activity index (DAI) of each mouse was rated using the same scoring system as previously discussed [18]. The score was the sum of parameters, including body weight loss (0 = none; 1 = 1-5%; 2 = 5-10%; 3 = 10-20%; 4 = 20%; 5 = >20%), stool consistency (0 = well-formed pellets; 1 = soft stool; 2 = loose stools; 3 = diarrhea; 4 = bloody diarrhea), and the presence or absence of fecal blood (0 = negative hemoccult test result; 2 = positive hemoccult test result; 4 = gross bleeding).…”

Section: Phenotype Evaluation Of Enteritis In Micementioning

confidence: 99%

Polysaccharide from Smilax glabra Roxb Mitigates Intestinal Mucosal Damage by Therapeutically Restoring the Interactions between Gut Microbiota and Innate Immune Functions

Abaidullah,

La,

Liu

et al. 2023

Nutrients

View full text Add to dashboard Cite

Smilax glabra Roxb (S. glabra) is a conventional Chinese medicine that is mainly used for the reliability of inflammation. However, bioactive polysaccharides from S. glabra (SGPs) have not been thoroughly investigated. Here, we demonstrate for the first time that SGPs preserve the integrity of the gut epithelial layer and protect against intestinal mucosal injury induced by dextran sulfate sodium. Mechanistically, SGPs mitigated colonic mucosal injury by restoring the association between the gut flora and innate immune functions. In particular, SGPs increased the number of goblet cells, reduced the proportion of apoptotic cells, improved the differentiation of gut tight junction proteins, and enhanced mucin production in the gut epithelial layer. Moreover, SGPs endorsed the propagation of probiotic bacteria, including Lachnospiraceae bacterium, which strongly correlated with decreased pro-inflammatory cytokines via the blocking of the TLR-4 NF-κB and MyD88 pathways. Overall, our study establishes a novel use of SGPs for the treatment of inflammatory bowel disease (IBD)-associated mucosal injury and provides a basis for understanding the therapeutic effects of natural polysaccharides from the perspective of symbiotic associations between host innate immune mechanisms and the gut microbiome.

show abstract

Microbiota from patients with ulcerative colitis promote colorectal carcinogenesis in mice

Cited by 6 publications

References 42 publications

Exopolysaccharides Produced by Bifidobacterium longum subsp. longum YS108R Ameliorates DSS-Induced Ulcerative Colitis in Mice by Improving the Gut Barrier and Regulating the Gut Microbiota

Exopolysaccharides Produced by Bifidobacterium longum subsp. longum YS108R Ameliorates DSS-Induced Ulcerative Colitis in Mice by Improving the Gut Barrier and Regulating the Gut Microbiota

Gut Microbiome–Colorectal Cancer Relationship

Polysaccharide from Smilax glabra Roxb Mitigates Intestinal Mucosal Damage by Therapeutically Restoring the Interactions between Gut Microbiota and Innate Immune Functions

Contact Info

Product

Resources

About